About us Editorial board Search Ahead of print Current issue Archives Instructions Subscribe Contacts Login 
Home Print this page Email this page Users Online: 531
ORIGINAL ARTICLE
Year : 2014  |  Volume : 2  |  Issue : 2  |  Page : 63-67

A comparative study between intravitreal ranibizumab and peripheral laser ablation in cases of prethreshold type I retinopathy of prematurity


Department of Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Correspondence Address:
Dr. Ahmed Mahmoud Abdel Hadi
24 Fawzy Moaz Street, Safwa 5, Entrance 2, Alexandria
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2347-5617.150211

Rights and Permissions

Purpose: The aim was to evaluate the efficacy and safety of intravitreal injection of ranibizumab for treatment of prethreshold type 1 retinopathy of prematurity (ROP) with conventional laser photocoagulation given for the same disease level. Subjects and Methods: In this retrospective comparative study, the charts of 16 premature babies, presenting from July 2009 to May 2014, were reviewed. All infants were diagnosed with prethreshold ROP (type 1). Patients received either intravitreal ranibizumab (0.625 mg/0.025 ml of solution) (group A, 12 eyes of 6 infants) or conventional diode laser (group B, 28 eyes of 14 infants), bilaterally. The main evaluated outcomes included time of regression, decrease of plus signs and incidence of recurrence. Infants were followed till 55 weeks postmenstrual age. The confidentiality of the patients was respected. Results: The mean age of the studied infants was 35.63 ± 1.58 weeks ranging from 33 to 39 weeks. The stage of ROP in the studied infants was either stage 2 in 7 cases (43.8%) or stage 3 in 9 cases (56.3%). The zones of ROP were zone I in 3 cases (18.8%) and zone II in 13 cases (81.3%). Group A had a mean gestational age (GA) of 36.6 ± 1.5 weeks, while cases in group B had mean GA of 35 ± 1.3 weeks. This was statistically significant (P = 0.037). The stage did not significantly affect the choice of treatment (P = 0.09). Looking at the subgroup analysis 66.7% (two cases) of cases with zone I disease were treated with intravitreal ranibizumab, whereas 69.2% (nine cases) with zone II disease were treated with conventional laser. The incidence of recurrence was not affected by the zone of the disease (P = 0.71) nor by the stage of the ROP or by the presence of plus sign (P = 0.29, P = 0.68, respectively). There was no statistically significant difference between the two treatment groups about the incidence of recurrence (P = 0.701). The mean GA for cases with recurrence of ROP (35.25 ± 2.6 weeks), did not differ significantly with the mean GA of the infants who did not suffer from recurrence 35.75 ± 1.2 weeks (P = 0.7). Conclusion: Both intravitreal ranibizumab and conventional laser were proven effective in the treatment of prethreshold type 1 ROP. Long-term favorable structural outcome may require extended observation and retreatment. Further large-scale studies are needed to address the long-term safety and efficacy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2382    
    Printed252    
    Emailed0    
    PDF Downloaded123    
    Comments [Add]    

Recommend this journal